Randomized, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE) First published 14/10/2021 Last updated 17/09/2025 EU PAS number:EUPAS43690 Study Finalised